China channel feed – Endpoints News

China channel feed

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

2 days ago

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

Last week

Sagimet's stock rises after China partner reports positive Phase 3 data in acne

Last week

Regeneron makes $80M obesity deal with Hansoh

Last week

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

Last week

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

3 weeks ago

TCG's R&D venture team makes a T cell engager deal with Shanghai biotech

3 weeks ago

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

4 weeks ago

Updated: Merck KGaA continues US tariff surcharge but at a 'decreased' rate

Last month

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

Last month

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Last month

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

Last month

AstraZeneca, Novartis execute ‘US for US’ strategy as pharma tariffs near

Last month

AstraZeneca posts another Truqap study fail, says China import tax could triple

Last month

WuXi AppTec sees growth after 2024 dip, plans ‘lean’ operations to temper ‘external opportunities’

Last month

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Last month

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Last month

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

Last month

Merck’s Gardasil sales sink further amid China market pressure

Last month

China’s biotech market is staging a comeback that US biotech can only wish for

Last month

Drugmakers stockpile inventory in the US, seeking to get ahead of Trump tariffs

Last month

China startup injects CRISPR therapy into the brain for the first time

Last month

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Last month

BioNTech-backed ADC maker DualityBio plans IPO on Hong Kong exchange

2 months ago

12 3 4 Next page Last page